{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:52:27Z","timestamp":1789537947737,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nelson syndrome (NS), or corticotroph tumor progression after bilateral adrenalectomy (CTP-BADX\/NS), is a serious complication in patients with Cushing disease (CD) following BADX. Surgical tumor removal is the recommended treatment, though adjuvant therapies may be necessary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim of the study<\/jats:title>\n                    <jats:p>To evaluate clinical, radiological, and hormonal features of CD patients after BADX, identify risk factors for CTP-BADX\/NS and assessed treatment outcome and cardio-metabolic complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study of 30 patients (male\/female: 9\/21; median age at CD diagnosis: 33 years, IQR 27\u201342) who underwent BADX and had a minimum follow-up of 18 months. Data were collected at diagnosis and during follow-up (6, 24 months and last visit).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a median follow-up of 135 months, 9\/30 patients (30%) developed NS, median 60 months after BADX. NS patients had earlier CD diagnosis and higher ACTH levels two years post-BADX [458 ng\/L (IQR 245\u2013723) vs. 146 ng\/L (61\u2013247),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.020]. They also took lower fludrocortisone [0.05\u00a0mg\/day vs. 0.1\u00a0mg\/day,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001] and tended to use less hydrocortisone [20\u00a0mg\/day [20\u201325] vs. 30 [25\u201330],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.06]. Pre-BADX stereotactic radiosurgery (SRS) was more frequent in non-NS patients (52% vs. 22%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.11).\n                    <\/jats:p>\n                    <jats:p>Hypertension was more common in NS patients (78% vs 43%), but diabetes less so (33% vs 48%). In the CTP-BADX group, 6\/9 required pituitary surgery and\/or radiotherapy; medical therapy was used in 5 patients with varied results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CTP-BADX\/NS occurred in 30% of cases in our cohort. Higher ACTH post-BADX and younger age at CD onset may predict NS. No hormonal or radiological markers reliably predicted tumor progression. SRS before BADX and higher hydrocortisone doses might offer protection. Tumor control often needed a multimodal approach, with limited success from medical therapy alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-025-01579-0","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T19:01:04Z","timestamp":1758913264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical presentation, predictive factors and management of patients with Nelson syndrome: a retrospective study"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9899-9328","authenticated-orcid":false,"given":"Pierluigi","family":"Mazzeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mondin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Voltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Manara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Caccese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Barbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"12","key":"1579_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1579_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00868-7","author":"M Fleseriu","year":"2023","unstructured":"Fleseriu M, Varlamov EV, Hinojosa-amaya JM, Langlois F, Melmed S (2023) An individualized approach to the management of Cushing disease. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-023-00868-7","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"1579_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jne.13113","volume":"34","author":"LT Braun","year":"2022","unstructured":"Braun LT, Vogel F, Reincke M (2022) Long-term morbidity and mortality in patients with Cushing\u2019s syndrome. J Neuroendocrinol 34(8):1\u201312. https:\/\/doi.org\/10.1111\/jne.13113","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"1579_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1530\/EJE-12-0921","volume":"168","author":"KI Alexandraki","year":"2013","unstructured":"Alexandraki KI, Kaltsas GA, Isidori AM, Storr HL, Afshar F, Sabin I, Akker SA, Chew SL, Drake WM, Monson JP, Besser GM, Grossman AB (2013) Long-term remission and recurrence rates in Cushing\u2019s disease: predictive factors in a single-centre study. Eur J Endocrinol 168(4):639\u2013648. https:\/\/doi.org\/10.1530\/EJE-12-0921","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1579_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s11102-014-0567-8","volume":"18","author":"G Aranda","year":"2015","unstructured":"Aranda G, Ense\u00f1at J, Mora M, Puig-Domingo M, Mart\u00ednez de Osaba MJ, Casals G, Verger E, Ribalta MT, Hanzu FA, Halperin I (2015) Long-term remission and recurrence rate in a cohort of Cushing\u2019s disease: the need for long-term follow-up. Pituitary 18(1):142\u2013149. https:\/\/doi.org\/10.1007\/s11102-014-0567-8","journal-title":"Pituitary"},{"key":"1579_CR6","doi-asserted-by":"publisher","unstructured":"Reincke M, Ritzel K, O\u00dfwald A, Berr C, Hallfeldt K, Reisch N et al (2014) A critical reappraisal of bilateral adrenalectomy for ACTH-dependent cushing\u2019 s syndrome. 2015;(October 12\u201314. https:\/\/doi.org\/10.1530\/EJE-15-0265","DOI":"10.1530\/EJE-15-0265"},{"issue":"4","key":"1579_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJM195807242590403","volume":"259","author":"JW NELSON DH, MEAKIN","year":"1958","unstructured":"NELSON DH, MEAKIN JW, THORN GW (1958) ACTH-producing tumor of the pituitary gland. N Engl J Med 259(4):161\u2013164. https:\/\/doi.org\/10.1056\/NEJM195807242590403. Jr","journal-title":"N Engl J Med"},{"issue":"3","key":"1579_CR8","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-20-1088","volume":"184","author":"M Reincke","year":"2021","unstructured":"Reincke M, Albani A, Assie G, Bancos I, Brue T, Buchfelder M et al (2021) Corticotroph tumor progression after bilateral adrenalectomy (Nelson\u2019s syndrome): systematic review and expert consensus recommendations. Eur J Endocrinol 184(3):P1\u2013P16. https:\/\/doi.org\/10.1530\/EJE-20-1088","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1579_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1210\/jc.2006-1328","volume":"92","author":"G Assi\u00e9","year":"2007","unstructured":"Assi\u00e9 G, Bahurel H, Coste J, Silvera S, Kujas M, Dugu\u00e9 MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing\u2019s disease: a reappraisal of Nelson\u2019s syndrome. J Clin Endocrinol Metab 92(1):172\u2013179. https:\/\/doi.org\/10.1210\/jc.2006-1328","journal-title":"J Clin Endocrinol Metab"},{"issue":"May","key":"1579_CR10","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BMK, Findling JW, Newell-price J, Savage MO, Stewart PM et al (2008) The diagnosis of cushing\u2019 s syndrome. Endocr Soc Clin Pract Guideline 93(May):1526\u20131540. https:\/\/doi.org\/10.1210\/jc.2008-0125","journal-title":"Endocr Soc Clin Pract Guideline"},{"issue":"6","key":"1579_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3343\/alm.2021.41.6.521","volume":"41","author":"S Pinelli","year":"2021","unstructured":"Pinelli S, Barbot M, Scaroni C, Ceccato F (2021) Second-line tests in the diagnosis of adrenocorticotropic hormone-dependent hypercortisolism. Ann Lab Med 41(6):521\u2013531. https:\/\/doi.org\/10.3343\/alm.2021.41.6.521","journal-title":"Ann Lab Med"},{"issue":"2","key":"1579_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101380","volume":"34","author":"M Barbot","year":"2020","unstructured":"Barbot M, Zilio M, Scaroni C (2020) Cushing\u2019s syndrome: overview of clinical presentation, diagnostic tools and complications. Best Pract Res Clin Endocrinol Metab 34(2):101380. https:\/\/doi.org\/10.1016\/j.beem.2020.101380","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"1579_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11102-015-0647-4","volume":"18","author":"M Fleseriu","year":"2015","unstructured":"Fleseriu M, Petersenn S (2015) Cushing disease: where do we stand, where are we heading? Pituitary 18(2):179\u2013180. https:\/\/doi.org\/10.1007\/s11102-015-0647-4","journal-title":"Pituitary"},{"issue":"4","key":"1579_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/s-2007-985196","volume":"17","author":"LJ Kim","year":"2007","unstructured":"Kim LJ, Lekovic GP, White WL, Karis J (2007) Preliminary experience with 3-Tesla MRI and cushing\u2019s disease. Skull Base 17(4):273\u2013277. https:\/\/doi.org\/10.1055\/s-2007-985196","journal-title":"Skull Base"},{"issue":"3","key":"1579_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3174\/ajnr.A7789","volume":"44","author":"M Castle-Kirszbaum","year":"2023","unstructured":"Castle-Kirszbaum M, Amukotuwa S, Fuller P, Goldschlager T, Gonzalvo A, Kam J, Kow CY, Shi MD, Stuckey S (2023) MRI for Cushing disease: a systematic review. AJNR Am J Neuroradiol 44(3):311\u2013316. https:\/\/doi.org\/10.3174\/ajnr.A7789","journal-title":"AJNR Am J Neuroradiol"},{"issue":"8","key":"1579_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13134","volume":"34","author":"M Losa","year":"2022","unstructured":"Losa M, Albano L, Bailo M, Barzaghi LR, Mortini P (2022) Role of radiosurgery in the treatment of Cushing\u2019s disease. J Neuroendocrinol 34(8):e13134. https:\/\/doi.org\/10.1111\/jne.13134","journal-title":"J Neuroendocrinol"},{"issue":"6","key":"1579_CR17","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3171\/2013.7.JNS13217","volume":"119","author":"JP Sheehan","year":"2013","unstructured":"Sheehan JP, Xu Z, Salvetti DJ, Schmitt PJ, Vance ML (2013) Results of gamma knife surgery for Cushing\u2019s disease. J Neurosurg 119(6):1486\u20131492. https:\/\/doi.org\/10.3171\/2013.7.JNS13217","journal-title":"J Neurosurg"},{"issue":"2","key":"1579_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1530\/EJE-14-0214","volume":"171","author":"A O\u00dfwald","year":"2014","unstructured":"O\u00dfwald A, Plomer E, Dimopoulou C, Milian M, Blaser R, Ritzel K, Mickisch A, Knerr F, Stanojevic M, Hallfeldt K, Schopohl J, Kuhn KA, Stalla G, Beuschlein F, Reincke M (2014) Favorable long-term outcomes of bilateral adrenalectomy in Cushing\u2019s disease. Eur J Endocrinol 171(2):209\u2013215. https:\/\/doi.org\/10.1530\/EJE-14-0214","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1579_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1210\/jcem.80.1.7829606","volume":"80","author":"PJ Jenkins","year":"1995","unstructured":"Jenkins PJ, Trainer PJ, Plowman PN, Shand WS, Grossman AB, Wass JA, Besser GM (1995) The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing\u2019s syndrome. J Clin Endocrinol Metab 80(1):165\u2013171. https:\/\/doi.org\/10.1210\/jcem.80.1.7829606","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1579_CR20","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jamcollsurg.2009.02.054","volume":"208","author":"PW Smith","year":"2009","unstructured":"Smith PW, Turza KC, Carter CO, Vance ML, Laws ER, Hanks JB (2009) Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy. J Am Coll Surg 208(6):1059\u20131064. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2009.02.054","journal-title":"J Am Coll Surg"},{"issue":"5","key":"1579_CR21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s11102-021-01158-z","volume":"24","author":"E Papakokkinou","year":"2021","unstructured":"Papakokkinou E, Piasecka M, Krage H, Dimitrios C, Olsson DS (2021) Prevalence of nelson\u2019 s syndrome after bilateral adrenalectomy in patients with Cushing \u2019 s disease: a systematic review and meta \u2013 analysis. Pituitary 24(5):797\u2013809. https:\/\/doi.org\/10.1007\/s11102-021-01158-z","journal-title":"Pituitary"},{"issue":"3","key":"1579_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1365-2265.1993.tb02371.x","volume":"39","author":"DR McCance","year":"1993","unstructured":"McCance DR, Russell CF, Kennedy TL, Hadden DR, Kennedy L, Atkinson AB (1993) Bilateral adrenalectomy: low mortality and morbidity in cushing\u2019s disease. Clin Endocrinol (Oxf) 39(3):315\u2013321. https:\/\/doi.org\/10.1111\/j.1365-2265.1993.tb02371.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1579_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1046\/j.1365-2265.1998.00578.x","volume":"49","author":"MA Pereira","year":"1998","unstructured":"Pereira MA, Halpern A, Salgado LR, Mendon\u00e7a BB, Nery M, Liberman B, Streeten DH, Wajchenberg BL (1998) A study of patients with Nelson\u2019s syndrome. Clin Endocrinol (Oxf) 49(4):533\u2013539. https:\/\/doi.org\/10.1046\/j.1365-2265.1998.00578.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1579_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.20945\/2359-3997000000144","volume":"63","author":"AC Cohen","year":"2019","unstructured":"Cohen AC, Goldney DC, Danilowicz K, Manavela M, Rossi MA, G\u00f3mez RM, Cross GE, Bruno OD (2019) Long-term outcome after bilateral adrenalectomy in Cushing\u2019s disease with focus on Nelson\u2019s syndrome. Arch Endocrinol Metab 63(5):470\u2013477. https:\/\/doi.org\/10.20945\/2359-3997000000144","journal-title":"Arch Endocrinol Metab"},{"issue":"7","key":"1579_CR25","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00701-021-04823-1","volume":"163","author":"A Bunevicius","year":"2021","unstructured":"Bunevicius A, Lavezzo K, Smith PW, Vance ML, Sheehan J (2021) Stereotactic radiosurgery before bilateral adrenalectomy is associated with lowered risk of nelson\u2019s syndrome in refractory cushing\u2019s disease patients. Acta Neurochir (Wien) 163(7):1949\u20131956. https:\/\/doi.org\/10.1007\/s00701-021-04823-1","journal-title":"Acta Neurochir (Wien)"},{"issue":"6","key":"1579_CR26","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3171\/2016.9.JNS161163","volume":"127","author":"CS Graffeo","year":"2017","unstructured":"Graffeo CS, Perry A, Carlstrom LP, Meyer FB, Atkinson JLD, Erickson D, Nippoldt TB, Young WF, Pollock BE, Van Gompel JJ (2017) Characterizing and predicting the Nelson-Salassa syndrome. J Neurosurg 127(6):1277\u20131287. https:\/\/doi.org\/10.3171\/2016.9.JNS161163","journal-title":"J Neurosurg"},{"issue":"7","key":"1579_CR27","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1210\/jcem.81.7.8675592","volume":"81","author":"N Sonino","year":"1996","unstructured":"Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro M (1996) Risk factors and long-term outcome in pituitary-dependent Cushing\u2019s disease. J Clin Endocrinol Metab 81(7):2647\u20132652. https:\/\/doi.org\/10.1210\/jcem.81.7.8675592","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1579_CR28","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1210\/jcem.79.3.8077377","volume":"79","author":"L Kemink","year":"1994","unstructured":"Kemink L, Pieters G, Hermus A, Smals A, Kloppenborg P (1994) Patient\u2019s age is a simple predictive factor for the development of Nelson\u2019s syndrome after total adrenalectomy for Cushing\u2019s disease. J Clin Endocrinol Metab 79(3):887\u2013889. https:\/\/doi.org\/10.1210\/jcem.79.3.8077377","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1579_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s002689910020","volume":"24","author":"SK Nagesser","year":"2000","unstructured":"Nagesser SK, van Seters AP, Kievit J, Hermans J, Krans HM, van de Velde CJ (2000) Long-term results of total adrenalectomy for cushing\u2019s disease. World J Surg 24(1):108\u2013113. https:\/\/doi.org\/10.1007\/s002689910020","journal-title":"World J Surg"},{"issue":"2","key":"1579_CR30","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.3171\/2014.10.FOCUS14681","volume":"38","author":"J Patel","year":"2015","unstructured":"Patel J, Eloy JA, Liu JK (2015) Nelson\u2019s syndrome: a review of the clinical manifestations, pathophysiology, and treatment strategies. Neurosurg Focus 38(2):E14. https:\/\/doi.org\/10.3171\/2014.10.FOCUS14681","journal-title":"Neurosurg Focus"},{"key":"1579_CR31","doi-asserted-by":"publisher","unstructured":"Bornstein SR, Allolio B, Arlt W, Barthel A, Don-wauchope A, Hammer GD et al (2016) Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2015-1710","DOI":"10.1210\/jc.2015-1710"},{"issue":"1","key":"1579_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF02739919","volume":"7","author":"K Kovacs","year":"1996","unstructured":"Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R, Althoff PH et al (1996) Pituitary corticotroph adenoma in a woman with long-standing Addison\u2019s disease: a histologic, immunocytochemical, electron microscopic, and in situ hybridization study. Endocr Pathol 7(1):91\u201397. https:\/\/doi.org\/10.1007\/BF02739919","journal-title":"Endocr Pathol"},{"issue":"6","key":"1579_CR33","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/MAJ.0000000000000305","volume":"349","author":"SJ Winters","year":"2015","unstructured":"Winters SJ, Vitaz T, Nowacki MR, Craddock DC, Silverman C (2015) Addison\u2019s disease and pituitary enlargement. Am J Med Sci 349(6):526\u2013529. https:\/\/doi.org\/10.1097\/MAJ.0000000000000305","journal-title":"Am J Med Sci"},{"issue":"10","key":"1579_CR34","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/neuonc\/noz109","volume":"21","author":"S Sbiera","year":"2019","unstructured":"Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E et al (2019) Driver mutations in USP8 wild-type cushing\u2019s disease. Neuro Oncol 21(10):1273\u20131283. https:\/\/doi.org\/10.1093\/neuonc\/noz109","journal-title":"Neuro Oncol"},{"issue":"12","key":"1579_CR35","doi-asserted-by":"publisher","first-page":"6824","DOI":"10.3390\/ijms23126824","volume":"23","author":"P Locantore","year":"2022","unstructured":"Locantore P, Paragliola RM, Cera G, Novizio R, Maggio E, Ramunno V, Corsello A, Corsello SM (2022) Genetic basis of ACTH-Secreting adenomas. Int J Mol Sci 23(12):6824. https:\/\/doi.org\/10.3390\/ijms23126824","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1579_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1530\/EJE-17-0634","volume":"178","author":"LG P\u00e9rez-Rivas","year":"2018","unstructured":"P\u00e9rez-Rivas LG, Theodoropoulou M, Puar TH, Fazel J, Stieg MR, Ferra\u00f9 F, Assi\u00e9 G, Gadelha MR, Deutschbein T, Fragoso et al (2018) Somatic USP8 mutations are frequent events in corticotroph tumor progression causing nelson\u2019s tumor. Eur J Endocrinol 178(1):57\u201363. https:\/\/doi.org\/10.1530\/EJE-17-0634","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1579_CR37","doi-asserted-by":"publisher","first-page":"e39114","DOI":"10.7759\/cureus.39114","volume":"15","author":"JA Torres-R\u00edos","year":"2023","unstructured":"Torres-R\u00edos JA, Romero-Luna G, Meraz Soto JM, Zavala-Romero L, Aguirre Maqueda ML, Rodr\u00edguez Camacho A, Moreno Jim\u00e9nez S (2023) Nelson\u2019s syndrome: A narrative review. Cureus 15(5):e39114. https:\/\/doi.org\/10.7759\/cureus.39114","journal-title":"Cureus"},{"key":"1579_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/623092","volume":"2015","author":"M E.Kurowska","year":"2015","unstructured":"E.Kurowska M, Nowakowski A, Zieli\u0144ski G, Malicka J, Tarach JS, Maksymowicz M et al (2015) Temozolomide-Induced shrinkage of invasive pituitary adenoma in patient with nelson\u2019s syndrome: A case report and review of the literature. Case Rep Endocrinol 2015:1\u20138. https:\/\/doi.org\/10.1155\/2015\/623092","journal-title":"Case Rep Endocrinol"},{"issue":"6","key":"1579_CR39","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1530\/EJE-10-0629","volume":"163","author":"M Losa","year":"2010","unstructured":"Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M et al (2010) Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 163(6):843\u2013851. https:\/\/doi.org\/10.1530\/EJE-10-0629","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1579_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1530\/EJE-08-0557","volume":"160","author":"VJ Moyes","year":"2009","unstructured":"Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K et al (2009) Treatment of Nelson\u2019s syndrome with temozolomide. Eur J Endocrinol 160(1):115\u2013119. https:\/\/doi.org\/10.1530\/EJE-08-0557","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1579_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1227\/01.NEU.0000339115.12803.4","volume":"64","author":"S Mohammed","year":"2009","unstructured":"Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD (2009) Use of Temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64(4):2\u20137. https:\/\/doi.org\/10.1227\/01.NEU.0000339115.12803.4","journal-title":"Neurosurgery"},{"issue":"4","key":"1579_CR42","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1530\/EJE-09-0414","volume":"161","author":"A Takeshita","year":"2009","unstructured":"Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K et al (2009) High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of cushing\u2019s disease. Eur J Endocrinol 161(4):553\u2013559. https:\/\/doi.org\/10.1530\/EJE-09-0414","journal-title":"Eur J Endocrinol"},{"issue":"20","key":"1579_CR43","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3760\/cma.j.issn.0376-2491.2018.20.001","volume":"98","author":"X Liu","year":"2018","unstructured":"Liu X, Wang R, Dai C (2018) Clinical significance of European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Natl Med J China 98(20):1537\u20131539. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2018.20.001","journal-title":"Natl Med J China"},{"issue":"4","key":"1579_CR44","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1227\/NEU.0000000000000251","volume":"74","author":"BE Zacharia","year":"2014","unstructured":"Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M et al (2014) High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and Temozolomide (CAPTEM): A case series. Neurosurgery 74(4):447\u2013455. https:\/\/doi.org\/10.1227\/NEU.0000000000000251","journal-title":"Neurosurgery"},{"key":"1579_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.731631","volume":"12","author":"O Mirallas","year":"2021","unstructured":"Mirallas O, Filippi-Arriaga F, Hernandez Hernandez I, Aubanell A, Chaachou A, Garcia-Alvarez A, Hernando J, Mart\u00ednez-Saez E, Biagetti B, Capdevila J (2021) Aggressive pituitary macroadenoma treated with capecitabine and temozolomide chemotherapy combination in a patient with nelson\u2019s syndrome: a case report. Front Endocrinol (Lausanne) 12:731631. https:\/\/doi.org\/10.3389\/fendo.2021.731631","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1579_CR46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.36401\/JIPO-22-25","volume":"6","author":"IJ Robertson","year":"2023","unstructured":"Robertson IJ, Gregory TA, Waguespack SG, Penas-Prado M, Majd NK (2023) Recent therapeutic advances in pituitary carcinoma. J Immunother Precis Oncol 6(2):74\u201383. https:\/\/doi.org\/10.36401\/JIPO-22-25","journal-title":"J Immunother Precis Oncol"},{"issue":"3","key":"1579_CR47","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11102-011-0346-8","volume":"15","author":"LD Ortiz","year":"2012","unstructured":"Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE et al (2012) Anti-VEGF therapy in pituitary carcinoma. Pituitary 15(3):445\u2013449. https:\/\/doi.org\/10.1007\/s11102-011-0346-8","journal-title":"Pituitary"},{"key":"1579_CR48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jocn.2017.02.052","volume":"41","author":"W Touma","year":"2017","unstructured":"Touma W, Hoostal S, Peterson RA, Wiernik A, SantaCruz KS, Lou E (2017) Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. J Clin Neurosci 41:75\u201377. https:\/\/doi.org\/10.1016\/j.jocn.2017.02.052","journal-title":"J Clin Neurosci"},{"issue":"1","key":"1579_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11102-011-0341-0","volume":"15","author":"E Jouanneau","year":"2012","unstructured":"Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J et al (2012) New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 15(1):37\u201343. https:\/\/doi.org\/10.1007\/s11102-011-0341-0","journal-title":"Pituitary"},{"issue":"2","key":"1579_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11102-006-9290-4","volume":"9","author":"I Shraga-Slutzky","year":"2006","unstructured":"Shraga-Slutzky I, Shimon I, Weinshtein R (2006) Clinical and biochemical stabilization of Nelson\u2019s syndrome with long-term low-dose cabergoline treatment. Pituitary 9(2):151\u2013154. https:\/\/doi.org\/10.1007\/s11102-006-9290-4","journal-title":"Pituitary"},{"issue":"6","key":"1579_CR51","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1159\/000082235","volume":"62","author":"LA Casulari","year":"2004","unstructured":"Casulari LA, Naves LA, Mello PA, Neto AP, Papadia C (2004) Nelson\u2019s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 62(6):300\u2013305. https:\/\/doi.org\/10.1159\/000082235","journal-title":"Horm Res"},{"issue":"11","key":"1579_CR52","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/BF03343660","volume":"22","author":"R Pivonello","year":"1999","unstructured":"Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A (1999) Complete remission of Nelson\u2019s syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 22(11):860\u2013865. https:\/\/doi.org\/10.1007\/BF03343660","journal-title":"J Endocrinol Invest"},{"key":"1579_CR53","unstructured":"Giovannetti C et al (2010) Use of cabergolin in Nelson\u2019s syndrome: preliminary results in four patients. Endocr Abstracts 22P564"},{"issue":"6","key":"1579_CR54","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1530\/acta.0.1200760","volume":"120","author":"SWJ Lamberts","year":"1989","unstructured":"Lamberts SWJ, Uitterlinden P, Klijn JMG (1989) The effect of the long-acting somatostatin analogue SMS 201\u2013995 on ACTH secretion in nelson\u2019s syndrome and cushing\u2019s disease. Acta Endocrinol (Copenh) 120(6):760\u2013766. https:\/\/doi.org\/10.1530\/acta.0.1200760","journal-title":"Acta Endocrinol (Copenh)"},{"key":"1579_CR55","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/pgmj.72.843.53","volume":"72","author":"F Kelestimur","year":"1996","unstructured":"Kelestimur F, Utas C, Selcuklu A, Kandemir O, Ozcan N (1996) The effects of octreotide. Postgrad Med J 72:53\u201354. https:\/\/doi.org\/10.1136\/pgmj.72.843.53","journal-title":"Postgrad Med J"},{"issue":"3","key":"1579_CR56","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11102-017-0853-3","volume":"21","author":"E Daniel","year":"2018","unstructured":"Daniel E, Debono M, Caunt S, Girio-Fragkoulakis C, Walters SJ, Akker SA et al (2018) A prospective longitudinal study of Pasireotide in nelson\u2019s syndrome. Pituitary 21(3):247\u2013255. https:\/\/doi.org\/10.1007\/s11102-017-0853-3","journal-title":"Pituitary"},{"issue":"1","key":"1579_CR57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40842-020-00110-7","volume":"6","author":"X He","year":"2020","unstructured":"He X, Spencer-Segal JL (2020) Rapid response of Nelson\u2019s syndrome to Pasireotide in radiotherapy-naive patient. Clin Diabetes Endocrinol 6(1):20\u201325. https:\/\/doi.org\/10.1186\/s40842-020-00110-7","journal-title":"Clin Diabetes Endocrinol"},{"issue":"10","key":"1579_CR58","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1055\/a-1158-9214","volume":"129","author":"SM Fill","year":"2021","unstructured":"Fill SM, Popp KH, Stalla GK, Athanasoulia-Kaspar AP (2021) Exceptional response of Nelson\u2019s syndrome to Pasireotide LAR in the long-term follow-up of 9 years. Exp Clin Endocrinol Diabetes 129(10):776\u2013778. https:\/\/doi.org\/10.1055\/a-1158-9214","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"1579_CR59","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1530\/EJE-15-0689","volume":"174","author":"K Hayashi","year":"2016","unstructured":"Hayashi K, Inoshita N, Kawaguchi K, Ardisasmita AI, Suzuki H, Fukuhara N et al (2016) The USP8 mutational status May predict drug susceptibility in corticotroph adenomas of cushing\u2019s disease. Eur J Endocrinol 174(2):213\u2013226. https:\/\/doi.org\/10.1530\/EJE-15-0689","journal-title":"Eur J Endocrinol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01579-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:12:26Z","timestamp":1778663546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01579-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1579"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01579-0","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}